Asad Haider, an analyst from Goldman Sachs, maintained the Hold rating on Pfizer. The associated price target remains the same with $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Asad Haider has given his Hold rating due to a combination of factors influencing Pfizer’s financial outlook. Despite a strong performance in the first quarter of 2025, driven by effective cost-cutting measures, the company’s future growth appears uncertain. The management’s guidance suggests they are nearing the upper end of their earnings per share range for 2025, yet the lack of new product cycles and uneven revenue performance pose challenges.
Moreover, while Pfizer has shown resilience and outperformed its peers recently, concerns remain about its ability to sustain this momentum. Key products like Vyndaqel and Ibrance, along with the COVID franchise, face competitive pressures and uncertain demand, which could impact future revenues. Additionally, the stability of COVID-related income is a crucial factor, as any deviation in expected trends could significantly affect earnings. Therefore, the Hold rating reflects the need for better clarity on revenue stability and growth prospects.
According to TipRanks, Haider is a 3-star analyst with an average return of 5.8% and a 69.23% success rate. Haider covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Merck & Company.
In another report released on July 23, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $28.00 price target.